Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer

被引：0
|
作者：
François Audenet
Adam M. Farkas
Harry Anastos
Matthew D. Galsky
Nina Bhardwaj
John P. Sfakianos
机构：
[1] Icahn School of Medicine at Mount Sinai,Department of Urology
[2] Icahn School of Medicine at Mount Sinai,Division of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute
来源：
World Journal of Urology | 2018年 / 36卷
关键词：
BCG; Immune checkpoints; Immune phenotype; Non-muscle invasive bladder cancer; Peripheral blood mononuclear cells; Predictive factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1741 / 1748
页数：7
相关论文
共 50 条
  • [31] PROGNOSTIC FACTOR OF CIRCULATING TUMOR CELLS IN HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER
    De Berardinis, Ettore
    Busetto, Gian Maria
    Sciarra, Alessandro
    Cristini, Cristiano
    Minisola, Francesco
    Di Pierro, Giovanni
    Petracca, Arianna
    Nicolazzo, Chiara
    Gazzaniga, Paola
    JOURNAL OF UROLOGY, 2010, 183 (04): : E376 - E376
  • [32] High-risk non-muscle invasive bladder cancer: Outcomes of patients who cannot benefit from standard of care
    Palkowski, Thomas
    Bibeau, Frederic
    Thiery-Vuillemin, Antoine
    Kleinclauss, Francois
    Frontczak, Alexandre
    FRENCH JOURNAL OF UROLOGY, 2025, 35 (03):
  • [33] Second transurethral resection for high-risk non-muscle invasive bladder cancer patients: a propensity score matched analysis
    Matsushita, Yuto
    Watanabe, Kyohei
    Watanabe, Hiromitsu
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    Miyake, Hideaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (06) : 718 - 721
  • [34] THE BURDEN OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER AMONG PATIENTS TREATED WITH BACILLUS CALMETTE-GUERIN
    Kopenhafer, L.
    Chang, J.
    Thompson, A.
    Sikirica, S.
    Masters, E. T.
    Cappelleri, J. C.
    Peck, E. Y.
    Maculaitis, M. C.
    VALUE IN HEALTH, 2022, 25 (07) : S557 - S557
  • [35] Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer
    Soltani-Tehrani, Amir M.
    Kumar, Aman
    Pohar, Kamal S.
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (11) : 6489 - 6502
  • [36] Incidence, initial management and survival of high-risk non-muscle invasive bladder cancer in Northern France
    Saint, Fabien
    Pasquier, David
    Villers, Arnauld
    Massa, Jordan
    Colin, Pierre
    Vankemmel, Olivier
    Leroy, Xavier
    Bonnal, Jean-Louis
    Plouvier, Sandrine D.
    FRENCH JOURNAL OF UROLOGY, 2024, 34 (09):
  • [37] Intravesical chemohyperthermia with mitomycin c for intermediate- & high-risk non-muscle invasive bladder cancer
    Lai, B. C. H.
    Wen, Y. -C.
    Shih, H. -J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 13 - 13
  • [38] Tumor mutation burden to predict progression in high-risk non-muscle invasive bladder cancer.
    Meeks, Joshua
    Carneiro, Benedito A.
    Pai, Sachin Gopalkrishn
    Oberlin, Daniel
    Rademaker, Alfred
    Fedorchak, Kyle
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [39] Role of Tissue Markers on Predicting the Prognosis of Intermediate and High-risk Non-muscle Invasive Bladder Cancer
    Abbasli, Abulfaz
    Citgez, Sinharib
    Demirdag, Cetin
    Gurbuz, Ahmet
    Erozenci, Ahmet
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2020, 19 (04): : 177 - 181
  • [40] Biomedical markers of response to intravesical BCG treatment in high-risk non-muscle invasive bladder cancer
    Jallad, S.
    Thomas, P.
    Newport, M.
    Kern, F.
    BRITISH JOURNAL OF SURGERY, 2014, 101 : 66 - 67
12345